Reuters: Global Markets: Osiris shares up as FDA clears reimbursement pathway for wound treatment

Reuters: Global Markets Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Osiris shares up as FDA clears reimbursement pathway for wound treatment May 30th 2012, 14:22 Wed May 30, 2012 10:32am EDT (Reuters) - Shares of Osiris Therapeutics Inc rose as much as 15 percent on Wednesday, after the stem-cell technology company's wound treatment received a temporary reimbursement code from U.S. health regulators. The U.S. Food and Drug Administration assigned a temporary reimbursement code for Osiris's wound-care matrix containing stem cells on Tuesday. The regulator also cleared the reimbursement pathway for the product by indicating that it could receive a permanent reimbursement code. Shares of the company were trading up 10 percent at $7.15 in morning trade on Wednesday on the Nasdaq. They jumped to $7.49 earlier in the session.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions